Shuttle Pharmaceuticals to Ring Nasdaq Opening Bell on Wednesday, January 18, 2023
Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) announced that its Chairman and CEO, Anatoly Dritschilo, will ring the Nasdaq opening bell on January 18, 2023. This event marks the company's recent IPO and highlights its commitment to developing therapies aimed at improving cancer treatment outcomes through radiation therapy. Dritschilo expressed excitement about their lead product candidate and the company's mission to enhance the effectiveness of radiation therapy while reducing side effects, aiming to benefit thousands of patients currently lacking effective treatment options.
- Successful IPO completion.
- Focus on developing radiation sensitizers to enhance cancer treatment outcomes.
- None.
ROCKVILLE, Md., Jan. 17, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes of cancer patients treated with radiation therapy (RT), today announced that Chairman and Chief Executive Officer, Anatoly Dritschilo, M.D., CEO, and other Shuttle Pharmaceuticals team members will ring the Nasdaq opening bell on Wednesday, January 18, 2023.
"Shuttle is excited to open the Nasdaq tomorrow morning to commemorate our recent IPO and the advancement of our lead product candidate aimed at improving the outcomes of cancer treatment through radiation therapy while reducing its side effects," commented Shuttle Pharma's Chairman and CEO, Anatoly Dritschilo, M.D. "We are excited about developing our platform of radiation sensitizers and the future opportunities it will bring as we work through our milestones and look to deliver innovative new treatments to thousands of patients who currently lack effective therapies."
The Opening Bell ceremony will be broadcast live starting at 9:15 a.m. Eastern Time from the Nasdaq MarketSite Tower in New York City, New York. To view the broadcast, please visit: https://www.nasdaq.com/marketsite/bell-ringing-ceremony.
About Shuttle Pharmaceuticals
Founded in 2012 by faculty members of the Georgetown University Medical Center, Shuttle Pharmaceuticals is a discovery and development stage specialty pharmaceutical company focused on improving the outcomes for cancer patients treated with radiation therapy (RT). Our mission is to improve the lives of cancer patients by developing therapies that are designed to maximize the effectiveness of RT while limiting the side effects of radiation in cancer treatment. Although RT is a proven modality for treating cancers, by developing radiation sensitizers, we aim to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment or in combination with surgery, chemotherapy and immunotherapy. For more information, please visit our website at www.shuttlepharma.com.
Safe Harbor Statement
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statements include, but are not limited to, statements concerning the development of our company. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including factors discussed in the "Risk Factors" section of Shuttle Pharma's IPO prospectus filed with the SEC on August 31, 2022, and any risk factors set forth in the Company's Quarterly Report on Form 10-Q filed with the SEC on November 14, 2022, or any other SEC filings. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, Shuttle Pharmaceuticals specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
Shuttle Pharmaceuticals
Anatoly Dritschilo, M.D., CEO
240-403-4212
info@shuttlepharma.com
Investor Contacts
Lytham Partners, LLC
Robert Blum
602-889-9700
shph@lythampartners.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/shuttle-pharmaceuticals-to-ring-nasdaq-opening-bell-on-wednesday-january-18-2023-301722980.html
SOURCE Shuttle Pharmaceuticals Holdings, Inc.
FAQ
What is the significance of Shuttle Pharmaceuticals ringing the Nasdaq opening bell?
When did Shuttle Pharmaceuticals ring the Nasdaq opening bell?
Who is the CEO of Shuttle Pharmaceuticals?
What is the focus of Shuttle Pharmaceuticals?
What are radiation sensitizers?
